Insider Trading Alert - ACAS, WST, MWE, ACT And WYN Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 2, 2013, 167 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $696.00 to $31,440,000.00.

Highlighted Stocks Traded by Insiders:

American Capital (ACAS) - FREE Research Report

Flax Samuel Allan who is EVP, GC and Secretary at American Capital sold 341 shares at $15.30 on Dec. 2, 2013. Following this transaction, the EVP, GC and Secretary owned 417,952 shares meaning that the stake was reduced by 0.08% with the 341-share transaction.

Graff Brian who is Senior Vice President at American Capital sold 1,981 shares at $15.17 on Dec. 2, 2013. Following this transaction, the Senior Vice President owned 153,854 shares meaning that the stake was reduced by 1.27% with the 1,981-share transaction.

The shares most recently traded at $15.16, down $0.01, or 0.06% since the insider transaction. Historical insider transactions for American Capital go as follows:

  • 4-Week # shares sold: 62,415
  • 12-Week # shares bought: 15,000
  • 12-Week # shares sold: 78,900
  • 24-Week # shares bought: 15,000
  • 24-Week # shares sold: 93,572

The average volume for American Capital has been 2.1 million shares per day over the past 30 days. American Capital has a market cap of $4.3 billion and is part of the financial sector and financial services industry. Shares are up 27.28% year-to-date as of the close of trading on Monday.

American Capital, Ltd. is a private equity and venture capital firm specializing in management and employee buyouts, leveraged finance, mezzanine, acquisition, recapitalization, middle market, and growth capital investments. The company has a P/E ratio of 23.9. Currently there are 3 analysts that rate American Capital a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACAS - FREE

TheStreet Quant Ratings rates American Capital as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full American Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

West Pharmaceutical Services (WST) - FREE Research Report

Morel Donald E Jr who is Chair of the Board & CEO at West Pharmaceutical Services sold 5,000 shares at $49.26 on Dec. 2, 2013. Following this transaction, the Chair of the Board & CEO owned 965,801 shares meaning that the stake was reduced by 0.52% with the 5,000-share transaction.

The shares most recently traded at $49.45, up $0.19, or 0.38% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 55,302
  • 12-Week # shares sold: 55,302
  • 24-Week # shares sold: 68,485

The average volume for West Pharmaceutical Services has been 249,100 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.5 billion and is part of the health care sector and health services industry. Shares are up 79.69% year-to-date as of the close of trading on Monday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.8%. The company has a P/E ratio of 32.2. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MarkWest Energy Partners (MWE) - FREE Research Report

Nickerson Randy S who is EVP, Chief Commercial Officer at MarkWest Energy Partners sold 1,500 shares at $68.73 on Dec. 2, 2013. Following this transaction, the EVP, Chief Commercial Officer owned 226,619 shares meaning that the stake was reduced by 0.66% with the 1,500-share transaction.

The shares most recently traded at $67.42, down $1.31, or 1.94% since the insider transaction. Historical insider transactions for MarkWest Energy Partners go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 23,000
  • 24-Week # shares sold: 27,500

The average volume for MarkWest Energy Partners has been 755,500 shares per day over the past 30 days. MarkWest Energy Partners has a market cap of $10.4 billion and is part of the basic materials sector and energy industry. Shares are up 33.11% year-to-date as of the close of trading on Monday.

Markwest Energy Partners, L.P., together with its subsidiaries, engages in the gathering, processing, and transportation of natural gas the United States. The stock currently has a dividend yield of 4.92%. The company has a P/E ratio of 141.0. Currently there are 8 analysts that rate MarkWest Energy Partners a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MWE - FREE

TheStreet Quant Ratings rates MarkWest Energy Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full MarkWest Energy Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis (ACT) - FREE Research Report

Wilkinson George Fred who is Pres-Actavis Specialty Brands at Actavis sold 24,217 shares at $165.00 on Dec. 2, 2013. Following this transaction, the Pres-Actavis Specialty Brands owned 15,412 shares meaning that the stake was reduced by 61.11% with the 24,217-share transaction.

The shares most recently traded at $145.10, down $19.90, or 13.71% since the insider transaction. Historical insider transactions for Actavis go as follows:

  • 12-Week # shares sold: 6,200
  • 24-Week # shares sold: 145,976

The average volume for Actavis has been 1.1 million shares per day over the past 30 days. Actavis has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 62.01% year-to-date as of the close of trading on Monday.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally.

Exclusive Offer: Get the latest Stock Analysis on ACT - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Wyndham Worldwide Corporation (WYN) - FREE Research Report

Buckman James E who is Director at Wyndham Worldwide Corporation sold 4,000 shares at $71.97 on Dec. 2, 2013. Following this transaction, the Director owned 9,576 shares meaning that the stake was reduced by 29.46% with the 4,000-share transaction.

The shares most recently traded at $72.82, up $0.85, or 1.17% since the insider transaction. Historical insider transactions for Wyndham Worldwide Corporation go as follows:

  • 4-Week # shares sold: 127,146
  • 12-Week # shares sold: 129,839
  • 24-Week # shares sold: 130,378

The average volume for Wyndham Worldwide Corporation has been 948,000 shares per day over the past 30 days. Wyndham Worldwide Corporation has a market cap of $9.3 billion and is part of the services sector and leisure industry. Shares are up 34.77% year-to-date as of the close of trading on Monday.

Wyndham Worldwide Corporation, together with its subsidiaries, provides various hospitality services and products to individual consumers and business customers in the United States and internationally. The stock currently has a dividend yield of 1.62%. The company has a P/E ratio of 22.8. Currently there are 5 analysts that rate Wyndham Worldwide Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WYN - FREE

TheStreet Quant Ratings rates Wyndham Worldwide Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Wyndham Worldwide Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Procter & Gamble Helps Lead Dow Jones After Upgrade From Morgan Stanley

Join Jim Cramer's Club During Our '12 Days of Holiday Deals' Sale and Save 66%!

Join Jim Cramer's Club During Our '12 Days of Holiday Deals' Sale and Save 66%!

Your Worst Enemy In a Bear Market Is Yourself

Your Worst Enemy In a Bear Market Is Yourself

Economist Perspective: Brexit Endgame in Sight?

Economist Perspective: Brexit Endgame in Sight?

Flashback Friday: Johnson & Johnson Hits Take Historic Plunge

Flashback Friday: Johnson & Johnson Hits Take Historic Plunge